RecruitingPhase 3NCT07142954

Epidemiology and Biomarker Study in Alzheimer's Disease

A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)

Sponsor

Eli Lilly and Company

Enrollment

3,400 participants

Start Date

Aug 25, 2025

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease

Summary

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

Eligibility

Min Age: 55 YearsMax Age: 75 Years

Inclusion Criteria2

The participant must self-report unimpaired cognition.
The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.

Exclusion Criteria4

Have seen a doctor about memory concerns.
Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition.
Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention.
Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine.